Recursion Pharmaceuticals, Inc. (RXRX) Stock Analysis — Probabli.AI
AI-powered analysis for RXRX (Recursion Pharmaceuticals, Inc.): probabilistic price forecasts, technical signals, peer comparison, institutional ownership, earnings history, and social sentiment. AI consensus: Bullish.
Last price: $3.07 · Market cap: $1.6B · AI consensus: Bullish
Recursion Pharmaceuticals, Inc. (RXRX) is positioned as a growth-oriented pharmaceutical stock leveraging AI-driven technologies and robust pipelines. The recent developments in drug trials and key partnerships signal substantial upside. While regulatory challenges and profitability concerns provide bearish scenarios, the overall sentiment remains bullish based on extraordinary revenue growth…
Probabilistic 1-Year Outlook
- Bull 4500% · Neutral 3500% · Bear 2000%
- Recursion Pharmaceuticals benefits from a strong revenue growth projection, positive pipeline developments, and favorable analyst sentiment. Despite some recent regulatory setbacks, the overall sentiment leans bullish…
5-Year Outlook
- Bull 6000% · Neutral 2500% · Bear 1500%
SWOT Highlights
- Strength: High projected revenue growth of 31280%.
- Strength: Innovative AI partnership enhancing drug discovery.
- Risk: Negative EPS estimates indicating unprofitability.
- Risk: Regulatory risks including FDA delays.
Major Catalysts
- [object Object]
- [object Object]
- [object Object]
Analyst Coverage & Dividends
4 Wall Street analysts rate RXRX a BUY with a mean price target of $7.5.
Analysis generated Apr 1, 2026 · Model: gpt-4o. Run a fresh analysis on probabli.xyz/stock/RXRX.
The information on this page is for educational and informational purposes only and does not constitute professional financial advice.